A Phase 0/2 Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma

Trial ID: NCT05577416

Interventional - Phase 1 - Completed

The aim of this clinical trial is to evaluate the feasibility of undertaking a Phase 0 surgical study in patients with diagnosis of a IDH1 mutated Low Grade Glioma (LGG) who have not received prior radiation or chemotherapy and are planned to undergo surgical resection.

Conditions

• Glioma

Interventions

• Biopsy
• Part A: Safusidenib Erbumine
• Surgery (maximal resection)
• Part B: Safusidenib Erbumine

Eligibility

Inclusion criteria

• 1. Histologically confirmed LGG or new diagnosis of LGG based on MRI
• 2. Tumours suitable for biopsy and safe for maximal resection in the opinion of the treating neurosurgeon
• 3. Patients who in the consensus of the treating neurosurgeon require resection of the brain tumour.
• 4. Patients who do not require immediate definitive resection of the brain tumour in the opinion of the treating neurosurgeon
• 5. Measurable and/or evaluable disease as per LGG-RANO criteria
• 6. Age ≥ 18 years of age.
• 7. ECOG performance score 0-1
• 8. Life expectancy of at least 24 months, in the opinion of the investigator
• 9. Adequate haematological, renal and hepatic function
• 10. Reproductive and contraception criteria as prescribed

Exclusion criteria

• Patients who meet any of the following criteria will be excluded from participation in the study:
• 1. Patients who require immediate definitive resection due to degree of mass effect or symptoms
• 2. Multicentric / multifocal tumour
• 3. Tumour involves cerebellum or brainstem
• 4. Patients who have undergone surgery for glioma within 24 months of study enrolment
• 5. Patients who have received prior chemotherapy and / or radiation for a diagnosis of glioma
• 6. Patients with contraindications to MRI or unwilling to undergo MRI
• 7. History of central nervous system bleeding as defined by stroke within 6 months before enrolment
• 8. Evidence of acute intracranial / intra-tumoural haemorrhage, except for participants with stable grade 1 haemorrhage
• 9. Other general criteria including:
• i) ECG abnormalities ii) significant comorbidity or infection iii) Prior malignancy iv) Recent surgery v) Known allergy or sensitivity to any of the excipients in the investigational product vi) no contraindicated concomitant medications
• 10. History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator would pose a risk to participant safety or interfere with the study evaluation, procedures or completion

Sponsor

Melbourne Health, Walter and Eliza Hall Institute of Medical Research, Nuvation Bio Inc.

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows